Esophageal cancer is a malignant growth that develops in the lining of the esophagus, the muscular tube that carries food from your throat to your stomach. It’s one of the more aggressive cancers, with survival depending heavily on how early it’s caught. When found before it spreads beyond the esophagus, the five-year survival rate is 49%. Once it reaches distant organs, that drops to 5%.
The Two Main Types
Esophageal cancer comes in two forms, and they behave quite differently. Adenocarcinoma starts in the gland cells that produce mucus in the lower part of the esophagus, near where it connects to the stomach. This is now the more common type in Western countries, driven largely by rising rates of obesity and chronic acid reflux. Squamous cell carcinoma develops in the flat cells lining the upper and middle sections of the esophagus and is more common in parts of Asia, Africa, and South America.
The distinction matters because each type has different risk factors and responds somewhat differently to treatment. Adenocarcinoma is closely tied to a condition called Barrett’s esophagus, where years of acid damage cause the normal esophageal lining to be replaced by tissue that resembles the intestinal lining. Squamous cell carcinoma is more strongly linked to tobacco and alcohol use.
Risk Factors for Each Type
Chronic acid reflux (GERD) is the single biggest driver of adenocarcinoma. When stomach acid repeatedly washes into the lower esophagus, it can trigger Barrett’s esophagus, which is considered a precancerous condition. The annual risk of Barrett’s progressing to adenocarcinoma is roughly 0.33% per year. That sounds small, but over a decade or two it adds up, especially when combined with other risk factors.
Obesity amplifies the risk substantially. Overweight individuals face about 1.4 times the risk of esophageal adenocarcinoma compared to people at a normal weight. For obese individuals, the risk jumps to roughly four times higher. People with a BMI above 40 face a sixfold increase. The combination of obesity and reflux is particularly dangerous: one study found that obese people with reflux had 16.5 times the risk of adenocarcinoma compared to non-obese people without reflux. The likely mechanism is straightforward. Excess abdominal fat increases pressure on the stomach, which pushes acid upward, which over time damages the esophageal lining and sets the stage for cancerous changes.
For squamous cell carcinoma, the primary risk factors are tobacco use and heavy alcohol consumption, especially together. Diets low in fruits and vegetables, drinking very hot beverages, and a history of certain esophageal conditions also contribute.
Symptoms and Warning Signs
Esophageal cancer is notoriously silent in its early stages. By the time symptoms appear, the tumor has often grown large enough to narrow the esophagus. The hallmark symptom is difficulty swallowing, known medically as dysphagia. It typically starts with solid foods feeling like they’re sticking or catching in the chest or behind the breastbone. Over weeks or months, swallowing liquids becomes difficult too.
Other warning signs include:
- Pain while swallowing, particularly a burning or pressure sensation in the chest
- Unexplained weight loss, often because eating becomes uncomfortable or impossible
- Chronic coughing or gagging when trying to swallow
- Food or acid backing up into the throat
- Hoarseness that doesn’t resolve
Because swallowing problems force people to eat less, malnutrition and dehydration are common by the time of diagnosis. If food regularly feels stuck in your chest, or you’ve lost weight without trying, those are symptoms worth investigating promptly.
How It’s Diagnosed
The primary diagnostic tool is an upper endoscopy with biopsies. A thin, flexible camera is passed down your throat to visually inspect the esophageal lining, and tissue samples are taken from any suspicious areas. This is considered essential for a definitive diagnosis.
Once cancer is confirmed, staging determines how far it has spread. Three imaging methods form the standard approach. Endoscopic ultrasound (EUS) is the most accurate way to assess how deeply the tumor has invaded the esophageal wall, with about 85 to 90% accuracy for evaluating tumor depth and 75% accuracy for detecting whether nearby lymph nodes are involved. It can also guide a fine-needle biopsy of suspicious lymph nodes. CT scans and PET-CT scans fill in the broader picture, revealing whether cancer has spread to distant organs like the liver or lungs.
Staging is what shapes the entire treatment plan, so it’s typically thorough. You can expect the diagnostic process to involve multiple tests over a few weeks.
Treatment Options
Treatment depends on the stage at diagnosis. For cancers caught very early, when only the superficial lining is affected, endoscopic procedures can sometimes remove the tumor without major surgery.
For locally advanced cancers that haven’t spread to distant sites, the standard approach is a combination of chemotherapy and radiation given before surgery. This pre-surgical treatment, called neoadjuvant chemoradiotherapy, typically involves about two cycles of chemotherapy with simultaneous radiation over several weeks. Surgery follows four to six weeks later, giving the body time to recover.
The surgery itself is called an esophagectomy, and it removes all or part of the esophagus along with a portion of the stomach. The remaining stomach (or sometimes a piece of the large intestine) is then pulled up and reconnected to create a new, shorter food tube. Two common techniques exist. A transhiatal approach uses incisions in the neck and abdomen. The Ivor Lewis approach uses incisions in the right side of the chest and abdomen. When possible, surgeons use minimally invasive techniques with small incisions, which can mean less pain and faster recovery.
Esophagectomy is a major operation. Recovery typically involves a hospital stay of one to two weeks, and it takes months to fully adjust to eating with a reconstructed digestive tract. Most people need to eat smaller, more frequent meals permanently.
Immunotherapy and Targeted Therapy
For advanced or metastatic esophageal cancer, treatment has expanded significantly in recent years. Immunotherapy drugs that help the immune system recognize and attack cancer cells are now part of standard treatment for many patients. These work by blocking proteins that cancer cells use to hide from immune detection. Several of these drugs, including pembrolizumab and nivolumab, are used either alone or combined with chemotherapy.
For adenocarcinomas that overproduce a specific growth-promoting protein called HER2, targeted therapies can be added to chemotherapy. These treatments zero in on that protein and block its ability to fuel tumor growth, sparing more of the healthy tissue that traditional chemotherapy would damage.
Survival by Stage
Based on data from people diagnosed between 2015 and 2021, five-year relative survival rates break down by how far the cancer has spread at diagnosis. Localized cancer, still confined to the esophagus, has a 49% five-year survival rate. Regional cancer, meaning it has reached nearby lymph nodes or tissues, drops to 28%. Distant cancer, where it has spread to other organs, carries a 5% five-year survival rate.
These numbers reflect averages across all patients and all treatment types. Individual outcomes vary based on overall health, how well the cancer responds to treatment, and the specific biology of the tumor. Still, the pattern is clear: early detection dramatically changes the outlook.
Screening and Prevention
There is no routine screening program for esophageal cancer in the general population. However, guidelines suggest that endoscopic screening may be worth considering for people who carry multiple risk factors for Barrett’s esophagus and adenocarcinoma. The typical profile is a man over 50 with chronic reflux symptoms lasting more than five years, who is white, and who has obesity or a large waist circumference. Having a first-degree relative with Barrett’s esophagus or esophageal adenocarcinoma lowers the threshold for considering screening.
For people already diagnosed with Barrett’s esophagus, periodic surveillance endoscopies are standard practice to watch for precancerous changes before they become invasive.
On the prevention side, the most impactful steps are managing chronic reflux effectively, maintaining a healthy weight (particularly reducing abdominal fat), avoiding tobacco, and limiting alcohol. For squamous cell carcinoma specifically, quitting smoking and reducing alcohol intake are the most protective measures available.